Bruker Announces New Microbiology Products and Workflows for Microbial Identification and Infection Control at ECCMID 2021
- New MBT Lipid Xtract™ Kit (RUO)* expands MALDI Biotyper®microbial analysis capabilities to lipids fingerprinting and to rapid colistin-resistance testing**
- Enhanced workflows include MBT FAST™Shuttle IVD and MBT Mycobacteria Kit (RUO)**
- MALDI Biotyper®Reference Libraries expansion to cover more than 4,000 species
- New IR Biotyper®3.1 software connects MALDI Biotyper®microbial species identification with IR Biotyper®strain-typing results for hospital hygiene**
BREMEN, Germany – July 14th, 2021 - At the 31st European Congress of Clinical Microbiology & Infectious Diseases (www.eccmid.org), Bruker today launched new products and methods for the market-leading MALDI Biotyper® (MBT) platform.
The MALDI Biotyper sirius® system supports workflows for the rapid, nearly universal and cost-effective microbial identification by ‘proteomic fingerprinting’ from culture plates and from positive blood cultures with the MBT Sepsityper® IVD Kit. Moreover, the unique MBT platform offers rapid functional antibiotic resistance testing with the MBT STAR®-Carba IVD and MBT STAR®-Cepha IVD Kits, and comprehensive mycobacteria analysis after culture.
The new MBT Lipid Xtract™ kit now expands the research capabilities into rapid lipid testing, even beyond rapid microbial identification. TheMBT Lipid Xtract™ Kit requires the negative ion mode of the MALDI Biotyper® sirius, and it can be used for fast and easy extraction of lipids. For example, certain lipid A modifications are considered as molecular markers for colistin resistance in gram-negative bacteria. Colistin is a crucial antibiotic of last resort in the fight against resistance.
Further product introductions include the MBT FAST™ Shuttle IVD (and RUO), a benchtop tool to standardize and optimize drying conditions for faster matrix crystallization and quicker drying of other droplet assays for sample preparation. The new MBT Mycobacteria kit is a preparation kit for mycobacteria after culture that allows fast sample preparation and safe inactivation by avoiding the need to boil mycobacteria samples. It is used in combination with the MBT Mycobacteria Library and software module which provides a reference library of 182 mycobacterium species.
The MALDI Biotyper® Reference Libraries have also been enhanced further: the MBT IVD Library has been expanded with 674 new species and now contains 3,813 species, while the MBT Mycobacteria (IVD and RUO) modules cover 182 Mycobacterium species, and the MBT Filamentous Fungi Suite (RUO) contains 247 species or species groups. Altogether, the MALDI Biotyper® Reference Libraries now cover over 4,000 species or species groups.
The new IR Biotyper® 3.1 software** connects the IR Biotyper®** for fast, easy and cost-effective strain typing for hospital hygiene management with the MALDI Biotyper®. The software is using state of the art classification tools based on artificial neural networks (ANN) to build models of known strains, serotypes or serogroups. Pre-defined models can be used for fast classification of unknown serotypes or serogroups, e.g., of Streptococcus pneumoniae, Listeria monocytogenes, Salmonella or Legionella pneumophila. The software includes new visualization tools to allow easier interpretation for classification or differentiation of strains.
Dr. Wolfgang Pusch, the Executive Vice President Microbiology and Diagnostics at Bruker Daltonics, concluded: “With the market-leading MALDI Biotyper® sirius and the new MBT Lipid Xtract™ Kit we have expanded our capabilities in microbiology and infectious disease from testing protein signatures to research on lipids as a new molecular window for microbial analysis. Moreover, with the IR Biotyper® 3.1 software our users can now use information on the microbial carbohydrate composition, another unique capability in microbial research and epidemiology.”
* Not for Sale in the USA
** Not for use in clinical diagnostics procedures
About the Bruker MALDI Biotyper®(MBT) Platform
The MALDI Biotyper® enables molecular identification of bacteria, yeasts and fungi. Classification and identification of microorganisms is achieved reliably and quickly using proteomic fingerprinting by high-throughput MALDI-TOF mass spectrometry. The MALDI Biotyper® uses a molecular approach based on specific proteomic fingerprints from bacterial strains. Many published studies have highlighted the greater accuracy and lower cost, as well as the typically much faster time-to-result (TTR).
Applications of various MALDI Biotyper® solutions include clinical routine microbial identification, environmental and pharmaceutical analysis, taxonomical research, food and consumer product safety and quality control, as well as marine microbiology. In many European and international laboratories, the MALDI Biotyper® has replaced classical biochemical testing for bacterial identification in the past years due to the accuracy, speed, extensive species coverage, ease of use and cost effectiveness of the system. Traditional biochemical techniques detect different metabolic properties of microorganisms, can take many hours or even days for completion, and they often lack specificity.
The robust MALDI Biotyper® requires minimal sample preparation and offers low consumables cost. The products of the MALDI Biotyper® family are available in a research-use-only (RUO) version, as the U.S. FDA-cleared MALDI Biotyper®CA System, or in an IVD-CE version according to EU directive EC/98/79. The MALDI Biotyper® also has medical device registrations in numerous other countries.
The MALDI Biotyper® software allows selected, high-value antimicrobial resistance tests. The CE-IVD MBT STAR®-Cepha Kit now allows rapid, functional antibiotic resistance testing against Cephalosporins, and the CE-IVD MBT STAR®-Carba Kit is for fast Carbapenem-resistance testing.
About Bruker Corporation
Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.
Investor Contact:
Miroslava Minkova
Director of Investor Relations and Corporate Development
T: +1 (978) 663–3660, ext. 1479
E: investor.relations@bruker.com
Contact for Media and Customers:
Philip Perry
Bruker Daltonics
T: +49-172-313-7216